Want to see AU:ARX full AI Analyst Report?

Aroa Biosurgery Ltd (ARX) Price & Analysis

62 Followers

ARX Stock Chart & Stats

AU$0.53

AU$0.00(0.00%)

At close: Jan 09 4:00 PM EST

AU$0.53

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.50 - AU$0.80

Previous CloseN/A

Volume195.72K

Average Volume (3M)302.12K

Market Cap

AU$195.43M

Enterprise ValueAU$196.49

Total Cash (Recent Filing)AU$22.60M

Total Debt (Recent Filing)AU$5.31M

Price to Earnings (P/E)31.9

Beta0.58

Next Earnings

Nov 26, 2026

EPS Estimate

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)0.02

Shares Outstanding345,902,650

10 Day Avg. Volume330,836

30 Day Avg. Volume302,123

Financial Highlights & Ratios

PEG Ratio-0.23

Price to Book (P/B)2.48

Price to Sales (P/S)2.23

P/FCF Ratio24.50

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

AU$1.08

Price Target Upside103.14% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering3

EPS Forecast (FY)0.01

Revenue Forecast (FY)AU$120.57M

Bulls Say, Bears Say

Bulls Say

Multi-year Revenue GrowthMulti-year revenue growth from ~A$20.5m in 2021 to ~A$92.3m in 2026 demonstrates scalable commercial traction and expanding clinical adoption. This durable top-line expansion supports capacity investments, channel development, and better fixed-cost absorption over coming quarters.

High Gross MarginsConsistently high gross margins (mid-80% range) reflect a proprietary ovine extracellular-matrix platform with pricing power and low incremental COGS. These margins provide structural ability to fund R&D, reimbursement support, and sales expansion, aiding sustainable profitability as volumes scale.

Conservative Balance SheetLow leverage (debt-to-equity ~0.06–0.08) and substantial equity (A$82.7–95.4m) give the company financial flexibility to invest in commercial expansion, absorb short-term shocks, and pursue OEM/distribution strategies without heavy reliance on external debt or dilutive capital.

Bears Say

Recent Profitability InflectionProfitability only turned positive in 2026 after multiple years of losses, and net margin remains modest (~4.5%). This limited margin buffer makes earnings sensitive to reimbursement pressure, pricing changes or cost inflation, raising execution risk if growth moderates.

Historical Cash-Flow VolatilityOperating and free cash flow swung positive in 2026 but were materially negative from 2021–2025, indicating volatile cash conversion. Until multiple consecutive positive periods are established, funding for expansion or unexpected costs could be constrained or require external financing.

Dependence On Distributors/OEMsHeavy reliance on third-party distributors and private-label/OEM relationships reduces direct control over commercialization, pricing and clinician adoption. This structural dependence can limit margin capture, slow brand equity development, and expose Aroa to partner strategy shifts over time.

Aroa Biosurgery Ltd News

Aroa Biosurgery Sets Fully Virtual 2026 AGM with Governance and CEO Incentive Votes

Aroa Biosurgery Ltd ( ($AU:ARX) ) has provided an announcement. Aroa Biosurgery Limited has scheduled its 2026 Annual...

14h ago

ARX

Aroa Biosurgery Cuts Potential Dilution as Options and Rights Lapse

Aroa Biosurgery Ltd ( ($AU:ARX) ) just unveiled an announcement. Aroa Biosurgery has notified the market of the...

11d ago

ARX

Aroa Biosurgery Welcomes CMS Plan to Keep Outpatient Skin Substitute Rates

Aroa Biosurgery Ltd ( ($AU:ARX) ) has shared an announcement. The United States Centers for Medicare & Medicaid...

11d ago

ARX

Aroa Biosurgery CFO James Agnew Resigns After 13 Years of Service

Aroa Biosurgery Ltd ( ($AU:ARX) ) has issued an announcement. Aroa Biosurgery announced that Chief Financial Officer and...

16d ago

ARX

Aroa Biosurgery Lodges Appendix 4G, Reaffirming ASX Governance Compliance

Aroa Biosurgery Ltd ( ($AU:ARX) ) has provided an update. Aroa Biosurgery Limited is a medical technology company...

25d ago

ARX

Aroa Biosurgery Sets Out 2026 Performance and Key Dates in Annual Report

Aroa Biosurgery Ltd ( ($AU:ARX) ) just unveiled an announcement. Aroa Biosurgery has released its annual report for...

25d ago

ARX

Aroa Biosurgery director trims indirect shareholding in on-market sale

Aroa Biosurgery Ltd ( ($AU:ARX) ) just unveiled an announcement. Aroa Biosurgery has disclosed a change in the...

26d ago

ARX

Aroa Biosurgery Sets AGM Date as Long-Serving Director Plans Retirement

Aroa Biosurgery Ltd ( ($AU:ARX) ) just unveiled an update. Aroa Biosurgery Ltd has scheduled its next Annual...

1M ago

ARX

Aroa Biosurgery Corrects Typo in FY26 Results Investor Presentation

Aroa Biosurgery Ltd ( ($AU:ARX) ) just unveiled an announcement. Aroa Biosurgery has issued a correction to its...

2M ago

ARX

Aroa Biosurgery Lifts FY26 Revenue 23% and Targets Further Growth With Higher FY27 Investment

Aroa Biosurgery Ltd ( ($AU:ARX) ) has provided an announcement. Aroa Biosurgery reported FY26 total revenue of NZ$103.9...

2M ago

ARX

ARX FAQ

What was Aroa Biosurgery Ltd’s price range in the past 12 months?

Aroa Biosurgery Ltd lowest share price was AU$0.49 and its highest was AU$0.80 in the past 12 months.

What is Aroa Biosurgery Ltd’s market cap?

Aroa Biosurgery Ltd’s market cap is AU$195.43M.

When is Aroa Biosurgery Ltd’s upcoming earnings report date?

Aroa Biosurgery Ltd’s upcoming earnings report date is Nov 26, 2026 which is in 125 days.

How were Aroa Biosurgery Ltd’s earnings last quarter?

Aroa Biosurgery Ltd released its earnings results on May 25, 2026. The company reported AU$0.017 earnings per share for the quarter, beating the consensus estimate of AU$0.004 by AU$0.012.

Is Aroa Biosurgery Ltd overvalued?

According to Wall Street analysts Aroa Biosurgery Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aroa Biosurgery Ltd pay dividends?

Aroa Biosurgery Ltd does not currently pay dividends.

What is Aroa Biosurgery Ltd’s EPS estimate?

Aroa Biosurgery Ltd’s EPS estimate is 0.

How many shares outstanding does Aroa Biosurgery Ltd have?

Aroa Biosurgery Ltd has 345,902,650 shares outstanding.

What happened to Aroa Biosurgery Ltd’s price movement after its last earnings report?

Aroa Biosurgery Ltd reported an EPS of AU$0.017 in its last earnings report, beating expectations of AU$0.004. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Aroa Biosurgery Ltd?

Currently, no hedge funds are holding shares in AU:ARX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Aroa Biosurgery Ltd Stock Smart Score

Neutral

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

1.55%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aroa Biosurgery Ltd

Aroa Biosurgery Limited operates as a regenerative medicine company dedicated to the development, production, and global distribution of medical solutions for wound and tissue repair. The firm innovatively utilizes extracellular matrix (ECM) technology, with its market presence spanning the United States and international territories. Its product line encompasses Endoform Natural and Endoform Antimicrobial Restorative Bioscaffold, tailored for managing both acute and chronic wounds. Additionally, the company offers Myriad Matrix, an engineered ECM device designed for soft tissue repair, reinforcement, and complex wound treatment, along with Myriad Morcells, a powdered version of Myriad Matrix serving similar soft tissue and complex wound applications. Rounding out its offerings are Reinforced Bioscaffolds, a specialized surgical product employed in ventral hernia repair and abdominal wall reconstruction. Founded in 2007, Aroa Biosurgery Limited is headquartered in Auckland, New Zealand.

Aroa Biosurgery Ltd (ARX) Earnings & Revenues

Historic Earnings Reports

ARX Stock 12 Month Forecast

Average Price Target

AU$1.08

▲(103.14% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"AU$2","-1":"-AU$1","-0.25":"-AU$0.25","0.5":"AU$0.5","1.25":"AU$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">AU$1.35</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.0766666666666669,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">AU$1.08</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.79,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">AU$0.79</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.59,0.6484615384615384,0.7069230769230769,0.7653846153846153,0.8238461538461539,0.8823076923076922,0.9407692307692308,0.9992307692307693,1.0576923076923077,1.1161538461538463,1.1746153846153846,1.233076923076923,1.2915384615384617,{"y":1.35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.59,0.6274358974358974,0.6648717948717948,0.7023076923076923,0.7397435897435898,0.7771794871794873,0.8146153846153847,0.8520512820512821,0.8894871794871796,0.9269230769230771,0.9643589743589744,1.001794871794872,1.0392307692307694,{"y":1.0766666666666669,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.59,0.6053846153846154,0.6207692307692307,0.6361538461538462,0.6515384615384615,0.666923076923077,0.6823076923076923,0.6976923076923077,0.713076923076923,0.7284615384615385,0.7438461538461538,0.7592307692307693,0.7746153846153847,{"y":0.79,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.56,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.68,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.78,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.73,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.64,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.66,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.655,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >